1. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003. 98:1802–1810.
Article
2. Mackey JR, Joy AA. Skeletal health in postmenopausal survivors of early breast cancer. Int J Cancer. 2005. 114:1010–1015.
Article
3. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005. 23:619–629.
Article
4. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004. 350:1081–1092.
Article
5. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003. 349:1793–1802.
Article
6. Harvey HA. Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy. Semin Oncol. 2004. 31:23–30.
Article
7. Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology. 2004. 67:390–396.
Article
8. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003. 21:4042–4057.
Article
9. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000. 88:1082–1090.
Article
10. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995. 10:1478–1487.
Article
11. Lowik CW, van der Pluijm G, van der Wee-Pals LJ, van Treslong-De Groot HB, Bijvoet OL. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. J Bone Miner Res. 1988. 3:185–192.
Article
12. Suzuki K, Takeyama S, Sakai Y, Yamada S, Shinoda H. Current topics in pharmacological research on bone metabolism: inhibitory effects of bisphosphonates on the differentiation and activity of osteoclasts. J Pharmacol Sci. 2006. 100:189–194.
Article
13. Green JR. Antitumor effects of bisphosphonates. Cancer. 2003. 97:840–847.
Article
14. Green JR, Clezardin P. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol. 2002. 25:S3–S9.
Article
15. Coleman RE. The clinical use of bone resorption markers in patients with malignant bone disease. Cancer. 2002. 94:2521–2533.
Article
16. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005. 23:4925–4935.
Article
17. Christenson RH. Biochemical markers of bone metabolism: an overview. Clin Biochem. 1997. 30:573–593.
Article
18. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clinical Chemistry. 1994. 40:2022–2025.
Article
19. Behr W, Barnert J. Quantification of bone alkaline phosphatase in serum by precipitation with wheat-germ lectin: a simplified method and its clinical plausibility. Clinical Chemistry. 1986. 32:1960–1966.
Article
20. Rosalki SB, Foo AY. Two new methods for separating and quantifying bone and liver alkaline phosphatase isoenzymes in plasma. Clinical Chemistry. 1984. 30:1182–1186.
Article
21. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002. 346:653–661.
Article
22. Brufsky A, Harker G, Beck T, Carroll R, Tan-Chiu E, Seidler C, et al. Zoledronic acid (ZA) for prevention of cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant Letrozole (Let): Preliminary results of the Z-FAST trial. 2004. Presented at the 2004 San Antonio Breast Cancer Symposium. [Abstract 1114].
23. Brufsky A, Harker W, Beck J, Carroll R, Tan-Chiu E, Seidler C, et al. Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant Letrozole (Let): 12 mos BMD results of the Z-FAST trial. Proc Am Soc Clin Oncol. 2005. 23:12.
Article
24. Davidson N, Neven P, Llombart A, Bundred N, Monnier A, DeBoer R, et al. Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer. Breast. 2005. 14:44.
25. Duda RJ Jr, O'Brien JF, Katzmann JA, Peterson JM, Mann KG, Riggs BL. Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease. J Clin Endocrinol Metab. 1988. 66:951–957.
Article
26. Coleman RE, Mashiter G, Fogelman I, Whitaker KD, Caleffi M, Moss DW, et al. Osteocalcin: a potential marker of metastatic bone disease and response to treatment. Eur J Cancer Clin Oncol. 1988. 24:1211–1217.
Article
27. Heaney RP. How does bone support calcium homeostasis? Bone. 2003. 33:264–268.
Article
28. Ueda M, Inaba M, Okuno S, Maeno Y, Ishimura E, Yamakawa T, et al. Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH. Life Sci. 2005. 77:1130–1139.
Article
29. Dresner-Pollak R, Mayer M, Hochner-Celiniker D. The decrease in serum bone-specific alkaline phosphatase predicts bone mineral density response to hormone replacement therapy in early postmenopausal women. Calcif Tissue Int. 2000. 66:104–107.
Article
30. Woitge HW, Pecherstorfer M, Li Y, Keck AV, Horn E, Ziegler R, et al. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res. 1999. 14:792–801.
Article